🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Safety and Efficacy of Papillary Versus NonPapillary Access During Percutaneous Nephrolithotomy

RecruitingNAAges 18 Years - anyAllAin Shams University
NCT07855354 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This study aims to evaluate and compare the safety, efficacy, and clinical outcomes of papillary and non-papillary renal access during percutaneous nephrolithotomy (PCNL), and to determine whether non-papillary puncture can be considered a safe and effective alternative to the conventional papillary approach in selected patients.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age ≥ 18 years * Solitary or multiple renal calculi ≥2 cm * Ability to provide informed consent Exclusion Criteria: * Bleeding diathesis or uncorrected coagulopathy * Active urinary tract infection at the time of surgery * Congenital anomalies severely distorting renal anatomy (e.g., horseshoe kidney, ectopic kidney) * Morbid obesity \[body mass index (BMI) ≥ 40\] limiting safe positioning * Pregnancy
💊

What it tests

  • Papillary access puncture
  • Non-papillary access puncture
📍

Where

1 site
Ain Shams University
Cairo, Egypt
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy